Alnylam Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 2/6
Alnylam Pharmaceuticals has a total shareholder equity of $-220.6M and total debt of $2.4B, which brings its debt-to-equity ratio to -1086.8%. Its total assets and total liabilities are $3.8B and $4.1B respectively.
Key information
-1,086.8%
Debt to equity ratio
US$2.40b
Debt
| Interest coverage ratio | n/a |
| Cash | US$2.44b |
| Equity | -US$220.64m |
| Total liabilities | US$4.05b |
| Total assets | US$3.83b |
Recent financial health updates
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?
Oct 25
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way?
Jun 21Recent updates
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking
Mar 19Is Alnylam's HELIOS-B Delay A Red Flag?
Mar 10Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think
Feb 18Alnylam's Huge Opportunity
Jan 12Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues
Dec 18Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares
Jun 23Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?
Oct 25Alnylam gets FDA nod for expanded use of rare disease drug Oxlumo
Oct 07Alnylam: Onpattro's Position In The ATTR Amyloidosis Cardiomyopathy Market
Sep 26Alnylam RNAi therapy for rare protein disorder gets EU approval
Sep 20Alnylam to offer $900M convertible senior notes
Sep 12Alnylam says trial of RNAi therapeutic cemdisiran achieves goals for IgA nephropathy
Aug 29Alnylam discovery of genetic mutations could lead to therapies for diabetes, obesity
Aug 18APOLLO Hits A Bullseye, And Alnylam Logs Another Major Clinical Win
Aug 04Alnylam to target abdominal obesity after research data on gene mutation
Jul 27Alnylam Pharmaceuticals Heading Toward A Key Trial Read-Out
Jul 19Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way?
Jun 21Financial Position Analysis
Short Term Liabilities: ALNY has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ALNY has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ALNY has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: ALNY's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable ALNY has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: ALNY is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 4.6% per year.